BindingDB logo
myBDB logout

36 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
21700453 56 Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.EBI MSD
21458261 55 The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.EBI MSD
19418631 15 Arginine vasopressin and its analogues--the influence of position 2 modification with 3,3-diphenylalanine enantiomers. Highly potent V2 agonists.EBI University of Gdansk
7752199 71 Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.EBI Medical College of Ohio
19800231 92 Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.EBI Schering-Plough Research Institute
17300166 88 Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.EBI INSERM
16297621 17 Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.EBI Wyeth Research
15857144 10 Design of benzophenone-containing photoactivatable linear vasopressin antagonists: pharmacological and photoreactive properties.EBI INSERM
1331448 101 Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.EBI Merck Research Laboratories
1732523 39 Preparation and biological activities of potential vasopressin photoaffinity labels.EBI University of Sherbrooke
15149662 71 Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.EBI Johnson and Johnson Pharmaceutical Research and Development
11755361 24 N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists.EBI Yamanouchi Pharmaceutical Co. Ltd.
21688787 295 New, potent, selective, and short-acting peptidic V1a receptor agonists.EBI Ferring Research Institute Inc.
20550119 96 Oral oxytocin antagonists.EBI DrugMolDesign
 5 Khusimol, a Non-Peptide Ligand for Vasopressin V1a ReceptorsEBI TBA
 66 Non-peptide oxytocin antagonists: identification and synthesis of a potent camphor aminosuccinimideEBI TBA
17942308 62 Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.EBI Johnson & Johnson Pharmaceutical Research & Development
12798333 56 Structure-activity study of novel tricyclic benzazepine arginine vasopressin antagonists.EBI Wyeth Research
12036368 59 Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.EBI Yamanouchi Pharmaceutical Co. Ltd.
11087564 30 Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.EBI Otsuka Pharmaceutical Company
10782666 46 The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.EBI Wyeth-Ayerst Research
10406633 32 5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists.EBI Wyeth-Ayerst Research
10406632 11 4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.EBI Wyeth-Ayerst Research
10340620 30 Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.EBI Merck Research Laboratories
9651149 54 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.EBI Wyeth-Ayerst Research
8784453 134 Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.EBI Otsuka Pharmaceutical Co.
8393113 114 Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.EBI Otsuka Pharmaceutical Co.
8126695 35 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.EBI Merck Research Laboratories
8021923 27 A new series of photoactivatable and iodinatable linear vasopressin antagonists.EBI UPR 9023 CNRS
7473590 37 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.EBI Merck Research Laboratories
17221184 55 Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates.BDB Columbia University
15131245 86 SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.BDB Sanofi-Synthelabo Recherche
11861823 10 Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.BDB Sanofi-Synthelabo Recherche
11082453 77 ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.BDB Abbott Laboratories
9864265 14 OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.BDB Second Tokushima Institute of New Drug Research
9223568 38 Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.BDB Yamanouchi Pharmaceutical Co., Ltd.